✦ LIBER ✦

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

✍ Scribed by Higuchi, Katsuhiko; Tanabe, Satoshi; Shimada, Ken; Hosaka, Hisashi; Sasaki, Eisaku; Nakayama, Norisuke; Takeda, Yuiti; Moriwaki, Toshikazu; Amagai, Kenji; Sekikawa, Takashi; Sakuyama, Toshikazu; Kanda, Tatsuo; Sasaki, Tohru; Azuma, Mizutomo; Takahashi, Fumiaki; Takeuchi, Masahiro; Koizumi, Wasaburo

Book ID: 122115314
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 750 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2014.01.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S-1 plus cisplatin versus S-1 alone for

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

✍ Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Aki 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 155 KB

6501 ORAL Global Lung Oncology Branch tr

6501 ORAL Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Rolski, J.; Grodzki, T.; Schneider, C.P.; Zatloukal, P.; Reck, M.; Aitini, E.; T 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB